Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2024;35(1):123-33
Article Links
Safety of COVID-19 Vaccine in Patients with Rheumatic and Musculoskeletal Diseases
Ali Abdulrahman Younis1, Asal Adnan Ridha2, Yasameen Abbas Humadi3, Nizar Abdulateef Jassim4, Nabaa Ihsan Awadh2, Avin Maroof5, Ali Mohammed Hussein Alqazzaz6, Faiq I. Gorial2, Taha Ahmed Qaradaghi7, Zahraa Salam Abdulzahra2, Zainab A. Mahmood8, Noor Talal Yaseen2, Duaa Nidhal AlIdrecy9, Israa Talib Hakman10, Saja Jabbar Tarfah10, Adil Saudi Khudhair10
Authors Information

1Department of Medicine, College of Medicine, University of Mosul, Mosul, Iraq

2Rheumatology Unit, Department of Internal Medicine, Baghdad Teaching Hospital, Medical City, Iraq

3Al-Nahrain University, College of Medicine, Baghdad, Iraq

4Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq

5School of Medicine, University of Kurdistan-Hawler, Erbil, Kurdistan Region, Iraq

6Department of Medicine, College of Medicine, University of Babylon, Iraq

7Sulaymaniyah Internal Medicine Teaching Hospital, Sulaymaniyah, Iraq

8College of Medicine, University of Basrah, Basrah, Iraq

9Al-Imamain Al-Kadhimin Medical City, Baghdad, Iraq

10Baghdad Teaching Hospital, Baghdad, Iraq

  

AA Younis, AA Ridha, YA Humadi, NA Jassim, NI Awadh, A Maroof, AMH Alqazzaz, FI Gorial, TA Qaradaghi, ZS Abdulzahra, ZA Mahmood, NT Yaseen, DN AlIdrecy, IT Hakman, SJ Tarfah, AS Khudhair

Keywords: COVID-19, vaccine, safety, rheumatic diseases, flare
References
  1. Responding to COVID-19 [Internet]. [cited 2022 Dec 19]. Available from: https://www.gavi.org/COVID19
  2. Li YK, Lui MPK, Yam LL, Cheng CS, Tsang THT, Kwok WS, et al. COVID‐19 vaccination in patients with rheumatic diseases: Vaccination rates, patient perspectives, and side effects. Immun Inflamm Dis 2022 Jan 31;10(3):e589.
  3. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 80(7):930-42. Doi: 10.1136/annrheumdis-2020-219498.
  4. CDC. COVID-19 Vaccination [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2022 Dec 19]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
  5. Boekel L, Hooijberg F, Besten YR, Vogelzang EH, Steenhuis M, Leeuw M, et al. COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases. Lancet Rheumatol 2022 May 1;4(5):e310–3.
  6. Iraq – COVID19 Vaccine Tracker [Internet]. [cited 2022 Dec 19]. Available from: https://COVID19.trackvaccines.org/country/iraq/
  7. Zavala-Flores E, Salcedo-Matienzo J, Quiroz-Alva A, Berrocal-Kasay A. Side Effects and Flares Risk After SARS-CoV-2 Vaccination in Patients With Systemic Lupus Erythematosus. Clin Rheumatol 2021;16:1–9. doi: 10.1007/s10067-021-05980-5
  8. Cherian S, Paul A, Ahmed S, Alias B, Manoj M, Santhosh AK, et al. Safety of the ChAdOx1 Ncov-19 and the BBV152 Vaccines in 724 Patients With Rheumatic Diseases: A Post-Vaccination Cross-Sectional Survey. Rheumatol Int 2021;41(8):1441–5. doi: 10.1007/s00296-021-04917-0
  9. Rotondo C, Cantatore FP, Fornaro M, Colia R, Busto G, Rella V, et al. Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study. Vaccines (Basel) 2021;9(7):730. doi: 10.3390/vaccines9070730
  10. Fan Y, Geng Y, Wang Y, Deng X, Li G, Zhao J, et al. Safety and Disease Flare of Autoimmune Inflammatory Rheumatic Diseases: A Large Real-World Survey on Inactivated COVID-19 Vaccines. Ann Rheum Dis 2022;81(3):443–5. doi: 10.1136/annrheumdis-2021-221736
  11. Visentini M, Gragnani L, Santini SA, Urraro T, Villa A, Monti M, et al. Flares of Mixed Cryoglobulinaemia Vasculitis After Vaccination Against SARS-CoV-2. Ann Rheum Dis (2022) 81(3):441–3. doi: 10.1136/annrheumdis-2021-221248
  12. Connolly CM, Ruddy JA, Boyarsky BJ, Barbur I, Werbel WA, Geetha D, et al. Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination. Arthritis Rheumatol (2022) 74(1):28–32. doi: 10.1002/art.41924
  13. Haslak F, Gunalp A, Cebi MN, Yildiz M, Adrovic A, Sahin S, et al. Early Experience of COVID-19 Vaccine-Related Adverse Events among Adolescents and Young Adults with Rheumatic Diseases: A Single-Center Study. Int J Rheum Dis (2022) 25(3):353–63. doi: 10.1111/1756-185X.14279
  14. Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K, et al. Disease Activity and Humoral Response in Patients With Inflammatory Rheumatic Diseases After Two Doses of the Pfizer mRNA Vaccine Against SARS-CoV-2. Ann Rheum Dis 2021;80(10):1317–21. doi: 10.1136/annrheumdis-2021-220503
  15. Fragoulis GE, Bournia VK, Mavrea E, Evangelatos G, Fragiadaki K, Karamanakos A, et al. COVID-19 Vaccine Safety and Nocebo-Prone Associated Hesitancy in Patients With Systemic Rheumatic Diseases: A Cross-Sectional Study. Rheumatol Int 2022;42(1):31–9. doi: 10.1007/s00296-021-05039-3
  16. Pinte L, Negoi F, Ionescu GD, Caraiola S, Balaban DV, Badea C, et al. COVID-19 Vaccine Does Not Increase the Risk of Disease Flare-Ups Among Patients With Autoimmune and Immune-Mediated Diseases. J Pers Med 2021;11(12):1283. doi: 10.3390/jpm11121283
  17. Barbhaiya M, Levine JM, Bykerk VP, Jannat-Khah D, Mandl LA. Systemic Rheumatic Disease Flares after SARS-CoV-2 Vaccination among Rheumatology Outpatients in New York City. Ann Rheum Dis 2021;80(10):1352–4. doi: 10.1136/annrheumdis-2021-220732
  18.  Spinelli FR, Favalli EG, Garufi C, Cornalba M, Colafrancesco S, Conti F, et al. Low Frequency of Disease Flare in Patients With Rheumatic Musculoskeletal Diseases Who Received SARS-CoV-2 mRNA Vaccine. Arthritis Res Ther 2022;24(1):21. doi: 10.1186/s13075-021-02674-w
  19. Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, et al. Early Experience of COVID-19 Vaccination in Adults with Systemic Rheumatic Diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021;7(3):e001814. doi: 10.1136/rmdopen-2021-001814
  20. Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi P, et al. Baseline Factors Associated With Self-Reported Disease Flares Following COVID-19 Vaccination among Adults with Systemic Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Rheumatol (Oxford) 2022;23:keac249. doi: 10.1093/rheumatology/keac249
  21. Tzioufas AG, Bakasis AD, Goules AV, Bitzogli K, Cinoku II, Chatzis LG, et al. A Prospective Multicenter Study Assessing Humoral Immunogenicity and Safety of the mRNA SARS-CoV-2 Vaccines in Greek Patients with Systemic Autoimmune and Autoinflammatory Rheumatic Diseases. J Autoimmun 2021;125:102743. doi: 10.1016/j.jaut.2021.102743
  22.  Felten R, Kawka L, Dubois M, Ugarte-Gil MF, Fuentes-Silva Y, Piga M, et al. Tolerance of COVID-19 Vaccination in Patients With Systemic Lupus Erythematosus: The International VACOLUP Study. Lancet Rheumatol 2021;3(9):e613–5. doi: 10.1016/S2665-9913(21)00221-6
  23.  Ozdede A, Guner S, Ozcifci G, Yurttas B, Toker Dincer Z, Atli Z, et al. Safety of SARS-CoV-2 Vaccination in Patients With Behcet's Syndrome and Familial Mediterranean Fever: A Cross-Sectional Comparative Study on the Effects of M-RNA Based and Inactivated Vaccine. Rheumatol Int 2022;4:1–15. doi: 10.1007/s00296-022-05119-y
  24.  Boekel L, Kummer LY, van Dam KPJ, Hooijberg F, van Kempen Z, Vogelzang EH, et al. Adverse Events After First COVID-19 Vaccination in Patients With Autoimmune Diseases. Lancet Rheumatol 2021;3(8):e542–5. doi: 10.1016/S2665-9913(21)00181-8
  25. Izmirly PM, Kim MY, Samanovic M, Fernandez-Ruiz R, Ohana S, Deonaraine KK, et al. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. Arthritis Rheumatol 2022;74(2):284–94. doi: 10.1002/art.41937
  26. Bixio R, Bertelle D, Masia M, Pistillo F, Carletto A, Rossini M. Incidence of Disease Flare After BNT162b2 Coronavirus Disease 2019 Vaccination in Patients With Rheumatoid Arthritis in Remission. ACR Open Rheumatol 2021;3(12):832–3. doi: 10.1002/acr2.11336
  27. Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, et al. Evaluation of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Immune-Mediated Inflammatory Diseases Up to 5 Months After Vaccination. Clin Exp Med 2021;5:1–9. doi: 10.1007/s10238-021-00771-3
  28.  Dimopoulou D, Spyridis N, Vartzelis G, Tsolia MN, Maritsi DN. Safety and Tolerability of the COVID-19 Messenger RNA Vaccine in Adolescents With Juvenile Idiopathic Arthritis Treated With Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol 2022;74(2):365–6. doi: 10.1002/art.41977
  29. Xie Y, Liu Y, Liu Y. The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review. Front Immunol 2022 Jul 4;13:919979. doi: 10.3389/fimmu.2022.919979
  30. Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. Safety of Vaccination Against SARS-CoV-2 in People With Rheumatic and Musculoskeletal Diseases: Results From the EULAR Coronavirus Vaccine (COVAX) Physician-Reported Registry. Ann Rheum Dis 2022;81(5):695–709. doi: 10.1136/annrheumdis-2021-221490
  31.  Fornaro M, Venerito V, Iannone F, Cacciapaglia F. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases. J Rheumatol 2022;49(3):334–5. doi: 10.3899/jrheum.210863
  32.  Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021;80:1330–8.
  33. Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al. Immunogenicity and safety of anti-SARS- CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021;80:1306–11.
  34. Ramirez GA, Della-Torre E, Moroni L, Yacoub M-R, Dagna L. Correspondence on ’Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’. Ann Rheum Dis 2021;80:e159.
  35. Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2021;80:1312–6.
  36. Li YK, Lui MPK, Yam LL, Cheng CS, Tsang THT, Kwok WS, et al. COVID‐19 vaccination in patients with rheumatic diseases: Vaccination rates, patient perspectives, and side effects. Immun Inflamm Dis 2022 Mar;10(3):e589.
  37. Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep 2021;11:22777.